Moderna, Merck mRNA cancer vaccine prevents melanoma from returning
An experimental personalized mRNA-based cancer vaccine from Merck and Moderna was successful at preventing melanoma from returning or spreading in a late-stage trial of high risk patients, the companies announced Wednesday.
The positive results mean a potentially life-extending treatment is one step closer to being available on the market.
They also herald a significant and...
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on thehill.com — the content belongs to The Hill.
